logo.jpg
Addex' Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson's Disease
January 04, 2016 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} FDA Orphan Drug Status Validates the...
logo.jpg
Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial
December 17, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 17 December 2015 -...
logo.jpg
Addex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuroprotective Agents
December 15, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 15 December 2015 -...
logo.jpg
Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis
December 09, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;}   Geneva, Switzerland, December 9, 2015...
logo.jpg
Addex Moves R&D Operations to Geneva's Campus Biotech
December 07, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, December 7, 2015 -...
logo.jpg
Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program
November 25, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;}   Geneva, Switzerland, 25 November 2015...
logo.jpg
Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neurodegenerative and Psychiatric Diseases
November 23, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;}   Geneva, Switzerland, 23 November...
logo.jpg
ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share
November 19, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;}   Geneva, Switzerland, 19 November...
logo.jpg
Addex' ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder
October 13, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Successful collaboration with the US...
logo.jpg
Addex Therapeutics Reports First Half 2015 Financial Results
September 30, 2015 01:00 ET | Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;}   Geneva, Switzerland, 30 September 2015...